Estrogen receptor alpha in human breast cancer: occurrence and significance - PubMed (original) (raw)
Review
Estrogen receptor alpha in human breast cancer: occurrence and significance
S Ali et al. J Mammary Gland Biol Neoplasia. 2000 Jul.
Abstract
Estrogens have long been recognized as being important for stimulating the growth of a large proportion of breast cancers. Now it is recognized that estrogen action is mediated by two receptors, and the presence of estrogen receptor alpha (ER alpha) correlates with better prognosis and the likelihood of response to hormonal therapy. Over half of all breast cancers overexpress ER alpha and around 70% of these respond to anti-estrogen (for example tamoxifen) therapy. In addition, the presence of elevated levels of ER alpha in benign breast epithelium appears to indicate an increased risk of breast cancer, suggesting a role for ER alpha in breast cancer initiation, as well as progression. However, a proportion of ER alpha-positive tumors does not respond to endocrine therapy and the majority of those that do respond eventually become resistant. Most resistant tumors remain ER alpha-positive and frequently respond to alternative endocrine treatment, indicative of a continued role for ER alpha in breast cancer cell proliferation. The problem of resistance has resulted in the search for and the development of diverse hormonal therapies designed to inhibit ER alpha action, while research on the mechanisms which underlie resistance has shed light on the cellular mechanisms, other than ligand binding, which control ER alpha function.
Similar articles
- Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS, Frasor J. Katzenellenbogen BS, et al. Semin Oncol. 2004 Feb;31(1 Suppl 3):28-38. doi: 10.1053/j.seminoncol.2004.01.004. Semin Oncol. 2004. PMID: 15052541 Review. - Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.
Kurebayashi J. Kurebayashi J. Breast Cancer. 2003;10(2):112-9. doi: 10.1007/BF02967635. Breast Cancer. 2003. PMID: 12736563 Review. - Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.
Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS. Shaaban AM, et al. Am J Surg Pathol. 2003 Dec;27(12):1502-12. doi: 10.1097/00000478-200312000-00002. Am J Surg Pathol. 2003. PMID: 14657709 - Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M. Saji S, et al. Cancer Res. 2002 Sep 1;62(17):4849-53. Cancer Res. 2002. PMID: 12208729 - Cracking the estrogen receptor's posttranslational code in breast tumors.
Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Le Romancer M, et al. Endocr Rev. 2011 Oct;32(5):597-622. doi: 10.1210/er.2010-0016. Epub 2011 Jun 15. Endocr Rev. 2011. PMID: 21680538 Review.
Cited by
- Esr1 but Not CYP19A1 Overexpression in Mammary Epithelial Cells during Reproductive Senescence Induces Pregnancy-Like Proliferative Mammary Disease Responsive to Anti-Hormonals.
Furth PA, Wang W, Kang K, Rooney BL, Keegan G, Muralidaran V, Zou X, Flaws JA. Furth PA, et al. Am J Pathol. 2023 Jan;193(1):84-102. doi: 10.1016/j.ajpath.2022.09.007. Epub 2022 Dec 1. Am J Pathol. 2023. PMID: 36464512 Free PMC article. - Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications.
Gandhi N, Das GM. Gandhi N, et al. Cells. 2019 Jan 26;8(2):89. doi: 10.3390/cells8020089. Cells. 2019. PMID: 30691108 Free PMC article. Review. - Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance.
Zhou Z, Song X, Chi JJ, Gius DR, Huang Y, Cristofanilli M, Wan Y. Zhou Z, et al. Cell Signal. 2020 Jun;70:109574. doi: 10.1016/j.cellsig.2020.109574. Epub 2020 Feb 19. Cell Signal. 2020. PMID: 32084531 Free PMC article. - Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium.
Chaudhuri O, Koshy ST, Branco da Cunha C, Shin JW, Verbeke CS, Allison KH, Mooney DJ. Chaudhuri O, et al. Nat Mater. 2014 Oct;13(10):970-8. doi: 10.1038/nmat4009. Epub 2014 Jun 15. Nat Mater. 2014. PMID: 24930031 - Estrogen deficiency - a central paradigm in age-related impaired healing?
El Mohtadi M, Whitehead K, Dempsey-Hibbert N, Belboul A, Ashworth J. El Mohtadi M, et al. EXCLI J. 2021 Jan 11;20:99-116. doi: 10.17179/excli2020-3210. eCollection 2021. EXCLI J. 2021. PMID: 33510594 Free PMC article. Review.
References
- J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):49-61 - PubMed
- Mol Cell Biol. 1998 Apr;18(4):1978-84 - PubMed
- Br J Cancer. 1982 Jan;45(1):80-5 - PubMed
- Eur J Cancer. 1999 May;35(5):744-6 - PubMed
- Genes Dev. 1998 Oct 15;12(20):3149-55 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical